Abstract:SUMMARY Many potential drug candidates pose potent anti-tumor activities, but they have either low solubility or high toxicities. We identified a novel Wnt pathway inhibitor, which displays anti-tumor activities through inhibition of tumor cell proliferations. However, it has low solubility and high toxicity. In our current study, we prepared RH40 micelles to encapsulate the drug, in order to improve its solubility and reduce its toxicity in animals. The micelle formulation could be administered intravenously and improve the drug distribution in tumor tissue/cells. Potentially, this strategy may allow us to overcome the hurdle of low solubility of drugs in order to improve their anti-tumor efficacy and reduce non-target toxicity. INTRODUCTION We have identified a novel compound CL010, which is an inhibitor targeting at the Wnt pathway. It was discovered through screening efforts using cell models for inhibiting signaling Wnt pathway. Our in vitro study indicated that it is highly potent in inhibiting growth and proliferation of cancer cells overexpressing of RSPO2/3. A few in vivo primary tumor models were established in order to test in vivo anti-tumor activities of CL010. However, CL010 was found to have very poor water solubility, which would restrict investigation of its dose responses in vivo. Therefore, improving the aqueous solubility of CL010 is essential before we can initiate in vivo studies to test its efficacy in animal models via different dosing schemes. In addition, the compound CL010 appeared to be toxic to mice when administered in vivo. Thus, the current study aims to improve the compound solubility and reduce its toxicity through micelle technology. EXPERIMENTAL METHODS 1. Preparation of micelle formulations containing the compound CL010: CL010 were dissolved in tert-butyl alcohol and mixed with water containing 20% cremophor RH40 and 5% mannitol. The solvents were removed by lyophilization. The lyophilized powder was then rehydrated with water. The anti-wnt compounds in micelles could increase its concentration to 3 mg/ml. This is a big improvement over its maximum solubility in water. (Table 1. Size distribution of the micelle) 2. Animal model setup: We select two gastric and one liver primary tumor samples, cut human tumor samples into 1 mm × 1 mm × 1 mm fragments, implant in 6-8 weeks old nude mice, start treatment when tumors reach 200 mm (length × width × width) / 2, dose mice via IV, and PO, and measure tumor size and bodyweight twice a week. RESULTS AND DISCUSSION We used the micelle formulation to prepare the CL010 compounds to dose animal via IV (Figure 1). The results show that there is difference in tumor sizes in the group treated with micelle-formulated CL010 compound, while the bodyweight of the treated mice were not reduced. Therefore, above studies demonstrated that micelle formulation improved the solubility of the compound CL010, and reduced its toxic effects on mice. Table1. Size distribution of the micelle with CL010 Figure1. In vivo testing of CL010 packed in micelle formulation on the Gastric #1 model. CONCLUSION Using an anti-Wnt pathway inhibitor, we have demonstrated that micelle formulations containing compound CL010 had improved its solubility. In addition, the micelle formation appears to reduce its toxic effects in vivo when given via IV. Therefore, we conclude that micelle formulation strategy may facilitate antitumor therapy by overcoming the hurdle of low solubility of drugs in order to improve their antitumor efficacy and reduce non-target toxicity. Currently, we are performing additional studies to search for better compositions of micelle formation, and to provide more solid in vivo data to provide evidence to support this strategy. REFERENCES 1. Genevieve. J; Robert, H.M. J Control Release 2010, 143, 2-12. 2. Ho-Chul. S; Adam W. G. Mol Pharmaceutics 2011, 8, 1257–1265. 200 60

An Anionic Long‐circulating Liposome That Improves Radioiodinated Antisense Oligonucleotide Delivery in Vitro and in Vivo

Delivery of Radioiodinated Antisense Oligonucleotides in Long Circulating Liposomes in Vivo

Anionic Long‐circulating Liposomes for Delivery of Radioiodinated Antisense Oligonucleotides

Multifunctional Nanoparticles Combining Host-Guest Interaction of Cb[7] and Auns for Light-Promoted Endosome Escape and High Gene Transfection

Preparation of Anionic Long Circulating Liposomes and Uptake by MCF-7 Breast Cancer Cells

In vitro and in vivo evaluation of cationic liposomes containing zoledronic acid as anticancer agent

Replacing cholesterol with asiatic acid to prolong circulation and enhance anti-metastatic effects of non-PEGylated liposomes

Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer

Telomerase-targeting antisense oligonucleotides carried by polycation liposomes enhance the growth inhibition effect on tumor cells.

Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy

Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2

Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

[The Effects of Antisense Oligonucleotides Bcl-2/Bcl-xl and Bcl-2 on Proliferation and Apoptosis of Breast Cancer Cells].

Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo.

In vitro and in vivo tumor suppressive activity induced by human telomerase transcriptase-targeting antisense oligonucleotides mediated by cationic liposomes.

In Vivo Anti-Tumor Efficacy Study of a Novel Wnt pathway Inhibitor Packed in RH 40 Micelles

Study on Biodistribution and Imaging of Radioiodinated Antisense Oligonucleotides in Nude Mice Bearing Human Lymphoma

Engineering Mesoporous Silica Nanoparticles for Targeted Alpha Therapy against Breast Cancer

[Anionic Long Circulation Liposomes Mediated Antisense Scintigraphy in Tumor-Bearing Rats].

Arginine-Modified Nanostructured Lipid Carriers with Charge-Reversal and Ph-Sensitive Membranolytic Properties for Anticancer Drug Delivery

Enhanced Growth Inhibition Effect of Antisense Oligonucleotides Mediated by Cationic Liposomes on HeLa Cells